BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 31781306)

  • 21. Contrast-Enhanced Ultrasound Biopsy of Sentinel Lymph Nodes in Patients with Breast Cancer: Implications for Axillary Metastases and Conservation.
    Cox K; Weeks J; Mills P; Chalmers R; Devalia H; Fish D; Sever A
    Ann Surg Oncol; 2016 Jan; 23(1):58-64. PubMed ID: 25990967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
    Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
    Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
    Pugliese MS; Karam AK; Hsu M; Stempel MM; Patil SM; Ho AY; Traina TA; Van Zee KJ; Cody HS; Morrow M; Gemignani ML
    Ann Surg Oncol; 2010 Apr; 17(4):1063-8. PubMed ID: 20033325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.
    Tadros AB; Wen HY; Morrow M
    Ann Surg Oncol; 2018 Oct; 25(11):3158-3164. PubMed ID: 30094484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.
    Stefanovic S; Diel I; Sinn P; Englert S; Hennigs A; Mayer C; Schott S; Wallwiener M; Blumenstein M; Golatta M; Heil J; Rom J; Sohn C; Schneeweiss A; Schuetz F; Domschke C
    Ann Surg Oncol; 2016 Mar; 23(3):757-66. PubMed ID: 26467455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.
    Yang Q; Ji G; Li J
    Cancer Biol Ther; 2020; 21(3):278-291. PubMed ID: 31696760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
    Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
    Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer.
    Xu JH; Wang Y; Xu D
    Cancer Biomark; 2019; 25(2):193-201. PubMed ID: 31104012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway.
    Zhang LY; Zhang YQ; Zeng YZ; Zhu JL; Chen H; Wei XL; Liu LJ
    Breast Cancer Res Treat; 2020 Jul; 182(1):21-33. PubMed ID: 32415497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer.
    Park TS; Thomas SM; Rosenberger LH; Fayanju OM; Plichta JK; Blitzblau RC; Ong CT; Hyslop T; Hwang ES; Greenup RA
    Ann Surg Oncol; 2018 Oct; 25(10):3019-3029. PubMed ID: 29978365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer.
    Wu MQ; Hu P; Gao J; Wei WD; Xiao XS; Tang HL; Li X; Ge QD; Jia WH; Liu RB; Xie XM
    Asian Pac J Cancer Prev; 2013; 14(1):287-92. PubMed ID: 23534739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers.
    Graff-Baker AN; Orozco JIJ; Marzese DM; Salomon MP; Hoon DSB; Goldfarb M
    Ann Surg Oncol; 2018 Oct; 25(10):3082-3087. PubMed ID: 29956094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.
    Giaginis C; Sampani A; Kotta-Loizou I; Giannopoulou I; Danas E; Politi E; Tsourouflis G; Kouraklis G; Patsouris E; Keramopoulos A; Nakopoulou L; Theocharis S
    Pathol Oncol Res; 2018 Jul; 24(3):631-640. PubMed ID: 28808873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer.
    Park MH; Kwon HJ; Kim JR; Lee B; Lee SJ; Bae YK
    Ann Surg Oncol; 2017 Nov; 24(12):3780-3787. PubMed ID: 28634667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
    Mamtani A; Patil S; Stempel MM; Morrow M
    Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.